Template:AHA AF guidelines
Jump to navigation
Jump to search
AHA/ACC/HRS AF (April 2014, adapted)[1]
- In patients with nonvalvular AF with prior stroke, TIA, or CHA2DS2-VASc score ≥2, recommend oral anticoagulation with:
- Warfarin, goal INR 2-3 (class I, level A)
- Dabigatran (class I, level B)
- Rivaroxaban (class I, level B)
- Apixaban (class I, level B)
- In patients with nonvalvular AF unable to maintain INR 2-3 with warfarin, recommend dabigatran, rivaroxaban, or apixaban (class I, level C)
- In patients with nonvalvular AF with moderate or severe CKD with CHA2DS2-VASc score ≥2, consider treatment with reduced doses of dabigatran, rivaroxaban, or apixaban, although safety has not yet been clearly delineated (class IIb, level C)
- In patients with ESRD, dabigatran and rivaroxaban are untested and are not recommended (class III, level C)
- In patients with a mechanical heart valve, do not use dabigatran (class III, level B)